- Home
- CRBU
as 11-21-2024 11:33am EST
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BERKELEY |
| Market Cap: | 236.3M | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $8.33 | Next Earning Date: | 11-06-2024 |
| Revenue: | $11,475,000 | Revenue Growth: | -66.85% |
| Revenue Growth (this year): | -66.22% | Revenue Growth (next year): | -11.15% |
Latest Caribou Biosciences Inc. News
CRBU Breaking Stock News: Dive into CRBU Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 hours ago
Caribou Biosciences to Participate in Upcoming Investor Conferences
Simply Wall St.
11 days ago
Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Simply Wall St.
13 days ago
Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
15 days ago
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
15 days ago
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Insider Monkey
21 days ago
Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?
GuruFocus.com
a month ago
STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc
GlobeNewswire
2 months ago
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
Compare CRBU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBU Caribou Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.